Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An overview of Clinical Quality Registries (CQRs) on gynecological oncology worldwide.
Baldewpersad Tewarie N, van Driel WJ, van Ham MAPC, Wouters MW, Rome RM, Høgdall CK, Pagano E, Hogberg T, Kruitwagen R; participants of the - Dutch Gynecological Oncology Group. Baldewpersad Tewarie N, et al. Among authors: van ham mapc. Eur J Surg Oncol. 2022 Oct;48(10):2094-2103. doi: 10.1016/j.ejso.2022.06.020. Epub 2022 Jun 23. Eur J Surg Oncol. 2022. PMID: 35931589 Free article. Review.
Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN, Kieffer JM, K Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham MAPC, Aalbers AG, Verwaal VJ, Van de Vijver KK, Sonke GS, van Driel WJ, Aaronson NK. Koole SN, et al. Among authors: van ham mapc. Eur J Surg Oncol. 2021 Jan;47(1):101-107. doi: 10.1016/j.ejso.2019.05.006. Epub 2019 May 13. Eur J Surg Oncol. 2021. PMID: 31128948 Clinical Trial.
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham M, van Dam P, Vuylsteke P, Bastings J, Kruitwagen RFPM, Lambrechts S, Olde Damink SWM, Rensen SS, Van Gorp T, Sonke GS, van Driel WJ. Ubachs J, et al. Gynecol Oncol. 2020 Dec;159(3):706-711. doi: 10.1016/j.ygyno.2020.09.042. Epub 2020 Oct 2. Gynecol Oncol. 2020. PMID: 33019981
Clinical auditing as an instrument to improve care for patients with ovarian cancer: The Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Eur J Surg Oncol. 2021 Jul;47(7):1691-1697. doi: 10.1016/j.ejso.2021.01.019. Epub 2021 Feb 5. Eur J Surg Oncol. 2021. PMID: 33581966 Free article.
Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Gynecol Oncol. 2021 Aug;162(2):331-338. doi: 10.1016/j.ygyno.2021.05.030. Epub 2021 Jun 17. Gynecol Oncol. 2021. PMID: 34147284 Free article.
Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
Tewarie NMSB, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group. Tewarie NMSB, et al. Gynecol Oncol. 2021 Dec;163(3):615. doi: 10.1016/j.ygyno.2021.09.019. Epub 2021 Oct 1. Gynecol Oncol. 2021. PMID: 34607710 Free article. No abstract available.
Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
Algera MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, Wouters MWJM; participants of the Dutch Gynecological Oncology Collaborator group. Algera MD, et al. Gynecol Oncol. 2022 May;165(2):330-338. doi: 10.1016/j.ygyno.2022.02.013. Epub 2022 Feb 22. Gynecol Oncol. 2022. PMID: 35221132 Free PMC article.
Guideline adherence in ovarian cancer for surgical staging in the Netherlands.
Baldewpersad Tewarie NMS, van Ham M, Wouters M, Kruitwagen R, van Driel W; participants of the Dutch Gynecological Oncology Collaborator Group; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Int J Gynecol Cancer. 2022 Dec 5;32(12):1592-1598. doi: 10.1136/ijgc-2022-003666. Int J Gynecol Cancer. 2022. PMID: 36270772
Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study.
Algera MD, Baldewpersad Tewarie NMS, Driel WJV, van Ham MAPC, Slangen BFM, Kruitwagen RFPM, Wouters MWJM; Participants of the Dutch Gynecological Oncology Audit Collaborator Group. Algera MD, et al. Among authors: van ham mapc. Int J Gynecol Cancer. 2023 Apr 3;33(4):534-542. doi: 10.1136/ijgc-2022-003981. Int J Gynecol Cancer. 2023. PMID: 36581486
47 results